WO2020222399A1 - 데슬로렐린을 포함하는 서방성 마이크로 입자 및 이의 제조 방법 - Google Patents
데슬로렐린을 포함하는 서방성 마이크로 입자 및 이의 제조 방법 Download PDFInfo
- Publication number
- WO2020222399A1 WO2020222399A1 PCT/KR2020/000657 KR2020000657W WO2020222399A1 WO 2020222399 A1 WO2020222399 A1 WO 2020222399A1 KR 2020000657 W KR2020000657 W KR 2020000657W WO 2020222399 A1 WO2020222399 A1 WO 2020222399A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mixture
- microparticles
- deslorelin
- sustained
- biodegradable polymer
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
함량기준 | 배합목적 | 성분명 | 분량 | 단위 |
2.0 mL | 등장화제 | D-만니톨(D-Mannitol) | 100.0 | mg |
현탁화제 | 카르복시메틸셀룰로오스나트륨(Soduim Carboxymethylcellulose) | 10.0 | mg | |
현탁화제 | 폴리소르베이트80(Polysorbate 80) | 10.0 | mg | |
용제 | 주사용수(Injection water) | 나머지 |
day | 실시예 1 | 실시예 2 | 실시예 3 | 실시예 4 | 실시예 5 | 실시예 6 |
0 | 0 | 0 | 0 | 0 | 0 | 0 |
0.02 | 32.60 | 29.88 | 27.85 | 35.00 | 15.30 | 3.49 |
0.04 | 38.83 | 34.63 | 30.73 | 40.3 | 17.32 | 5.53 |
0.06 | 44.97 | 41.87 | 39.6 | 47.1 | 20.6 | 6.49 |
0.08 | 42.47 | 44.46 | 23.4 | 50.3 | 21.7 | 7.51 |
0.10 | 46.80 | 48.80 | 28.80 | 50.40 | 21.90 | 8.70 |
0.13 | 50.53 | 48.52 | 32.53 | 53.70 | 23.70 | 9.42 |
0.17 | 47.03 | 46.23 | 33.67 | 65.80 | 22.75 | 10.42 |
0.25 | 62.60 | 58.61 | 29.53 | 70.60 | 24.64 | 12.24 |
0.33 | 50.93 | 56.91 | 29.03 | 76.30 | 25.86 | 12.12 |
0.50 | 35.67 | 55.47 | 17.27 | 65.20 | 26.75 | 13.24 |
1.00 | 23.32 | 33.40 | 12.38 | 51.80 | 23.46 | 11.05 |
7 | 33.25 | 34.27 | 9.13 | 35.70 | 22.45 | 15.64 |
14 | 20.51 | 28.10 | 25.73 | 25.73 | 20.71 | 16.50 |
21 | 24.01 | 26.46 | 33.63 | 0.00 | 20.66 | 20.21 |
28 | 2.78 | 5.78 | 20.03 | 0.00 | 18.21 | 31.62 |
35 | 0.00 | 3.45 | 16.50 | 0.00 | 17.55 | 24.34 |
42 | 0.00 | 2.25 | 15.80 | 0.00 | 17.21 | 25.71 |
49 | 0.00 | 1.51 | 10.47 | 0.00 | 16.43 | 26.46 |
56 | 0.00 | 0.00 | 9.51 | 0.00 | 14.59 | 22.43 |
63 | 0.00 | 0.00 | 8.71 | 0.00 | 13.84 | 20.87 |
70 | 0.00 | 0.00 | 8.59 | 0.00 | 12.54 | 20.67 |
77 | 0.00 | 0.00 | 6.53 | 0.00 | 11.62 | 18.51 |
84 | 0.00 | 0.00 | 5.49 | 0.00 | 7.53 | 17.05 |
91 | 0.00 | 0.00 | 1.54 | 0.00 | 5.19 | 16.59 |
Claims (14)
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2021012923A MX2021012923A (es) | 2019-04-30 | 2020-01-14 | Microparticulas de liberacion sostenida que contienen deslorelina, y metodo de preparacion de las mismas. |
JP2021563253A JP7253287B2 (ja) | 2019-04-30 | 2020-01-14 | デスロレリンを含む徐放性マイクロ粒子およびその調製方法 |
EP20799171.2A EP3949951A4 (en) | 2019-04-30 | 2020-01-14 | DELAYED-RELEASE MICROPARTICLES WITH DESLORELIN AND PRODUCTION PROCESS THEREOF |
AU2020266058A AU2020266058B2 (en) | 2019-04-30 | 2020-01-14 | Sustained-release microparticles containing deslorelin, and preparation method therefor |
US17/605,185 US20220202894A1 (en) | 2019-04-30 | 2020-01-14 | Sustained-release microparticles containing deslorelin, and preparation method therefor |
SG11202111521WA SG11202111521WA (en) | 2019-04-30 | 2020-01-14 | Sustained-release microparticles containing deslorelin, and preparation method therefor |
CN202080031675.6A CN113747884A (zh) | 2019-04-30 | 2020-01-14 | 包含地洛瑞林的缓释型微粒及其制备方法 |
PE2021001759A PE20220491A1 (es) | 2019-04-30 | 2020-01-14 | Microparticulas de liberacion sostenida que contienen deslorelina, y metodo de preparacion de las mismas |
CA3137819A CA3137819C (en) | 2019-04-30 | 2020-01-14 | Sustained-release microparticles containing deslorelin, and preparation method therefor |
IL287361A IL287361A (en) | 2019-04-30 | 2021-10-18 | Sustained-release microparticles containing desulorin and a method for making them |
ZA2021/08300A ZA202108300B (en) | 2019-04-30 | 2021-10-27 | Sustained-release microparticles containing deslorelin, and preparation method therefor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190050437A KR102249104B1 (ko) | 2019-04-30 | 2019-04-30 | 데슬로렐린을 포함하는 서방성 마이크로 입자 및 이의 제조 방법 |
KR10-2019-0050437 | 2019-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020222399A1 true WO2020222399A1 (ko) | 2020-11-05 |
Family
ID=73028838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2020/000657 WO2020222399A1 (ko) | 2019-04-30 | 2020-01-14 | 데슬로렐린을 포함하는 서방성 마이크로 입자 및 이의 제조 방법 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220202894A1 (ko) |
EP (1) | EP3949951A4 (ko) |
JP (1) | JP7253287B2 (ko) |
KR (1) | KR102249104B1 (ko) |
CN (1) | CN113747884A (ko) |
AU (1) | AU2020266058B2 (ko) |
CA (1) | CA3137819C (ko) |
CL (1) | CL2021002761A1 (ko) |
IL (1) | IL287361A (ko) |
MX (1) | MX2021012923A (ko) |
PE (1) | PE20220491A1 (ko) |
SG (1) | SG11202111521WA (ko) |
WO (1) | WO2020222399A1 (ko) |
ZA (1) | ZA202108300B (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024003291A1 (en) | 2022-06-30 | 2024-01-04 | Virbac | Deslorelin use in chemical castration of a non-human mammal related to pk/pd interaction |
WO2024003288A1 (en) * | 2022-06-30 | 2024-01-04 | Virbac | Deslorelin for attenuation of animal urine odor |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230124229A (ko) * | 2022-02-18 | 2023-08-25 | (주)인벤티지랩 | 데슬로렐린을 포함하는 서방성 주사용 조성물 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1045625A (ja) * | 1996-04-30 | 1998-02-17 | Takeda Chem Ind Ltd | 医薬組成物 |
US20020052320A1 (en) * | 1996-08-30 | 2002-05-02 | Peptech Limited | Sustained peptide-release formulation |
WO2007084460A2 (en) * | 2006-01-18 | 2007-07-26 | Qps, Llc | Pharmaceutical compositions with enhanced stability |
KR20120052355A (ko) | 2009-07-28 | 2012-05-23 | 마르셀로 비바쿠아 | 수컷 포유동물에서 성적 불임화 및 리비도 억제를 위한 화학적 방법 |
KR101583351B1 (ko) * | 2014-11-28 | 2016-01-07 | 동국제약 주식회사 | 초기 방출 억제 및 잔류용매 제거율을 향상시킨 서방출성 미립구 및 이의 제조방법 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4166590B2 (ja) | 2003-02-04 | 2008-10-15 | 独立行政法人科学技術振興機構 | ダブルエマルション・マイクロカプセル生成装置 |
DK1824460T3 (en) * | 2004-11-10 | 2015-01-19 | Tolmar Therapeutics Inc | Stabilized polymeric delivery system |
CN105287390A (zh) * | 2015-11-20 | 2016-02-03 | 北京博恩特药业有限公司 | 一种长效醋酸亮丙瑞林微球及其制备方法 |
WO2017150824A1 (ko) | 2016-03-03 | 2017-09-08 | 가천대학교 산학협력단 | 마이크로 니들 및 이의 제조방법 |
-
2019
- 2019-04-30 KR KR1020190050437A patent/KR102249104B1/ko active IP Right Grant
-
2020
- 2020-01-14 US US17/605,185 patent/US20220202894A1/en active Pending
- 2020-01-14 AU AU2020266058A patent/AU2020266058B2/en active Active
- 2020-01-14 EP EP20799171.2A patent/EP3949951A4/en active Pending
- 2020-01-14 WO PCT/KR2020/000657 patent/WO2020222399A1/ko unknown
- 2020-01-14 PE PE2021001759A patent/PE20220491A1/es unknown
- 2020-01-14 JP JP2021563253A patent/JP7253287B2/ja active Active
- 2020-01-14 SG SG11202111521WA patent/SG11202111521WA/en unknown
- 2020-01-14 CN CN202080031675.6A patent/CN113747884A/zh active Pending
- 2020-01-14 MX MX2021012923A patent/MX2021012923A/es unknown
- 2020-01-14 CA CA3137819A patent/CA3137819C/en active Active
-
2021
- 2021-10-18 IL IL287361A patent/IL287361A/en unknown
- 2021-10-20 CL CL2021002761A patent/CL2021002761A1/es unknown
- 2021-10-27 ZA ZA2021/08300A patent/ZA202108300B/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1045625A (ja) * | 1996-04-30 | 1998-02-17 | Takeda Chem Ind Ltd | 医薬組成物 |
US20020052320A1 (en) * | 1996-08-30 | 2002-05-02 | Peptech Limited | Sustained peptide-release formulation |
WO2007084460A2 (en) * | 2006-01-18 | 2007-07-26 | Qps, Llc | Pharmaceutical compositions with enhanced stability |
KR20120052355A (ko) | 2009-07-28 | 2012-05-23 | 마르셀로 비바쿠아 | 수컷 포유동물에서 성적 불임화 및 리비도 억제를 위한 화학적 방법 |
KR101583351B1 (ko) * | 2014-11-28 | 2016-01-07 | 동국제약 주식회사 | 초기 방출 억제 및 잔류용매 제거율을 향상시킨 서방출성 미립구 및 이의 제조방법 |
Non-Patent Citations (3)
Title |
---|
KINOSHITA, K. ET AL.: "From single microparticles to microfluidic emulsification: fundamental properties (solubility, density, phase separation) from micropipette manipulation of solvent, drug and polymer microspheres", PROCESSES, vol. 4, no. 49, 2016, pages 1 - 28, XP055594903, DOI: 10.3390/pr4040049 * |
See also references of EP3949951A4 |
THUN R ET AL.: "Castration in male pigs: Techniques and animal welfare issues", JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, vol. 57, 2006, pages 189 - 194 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024003291A1 (en) | 2022-06-30 | 2024-01-04 | Virbac | Deslorelin use in chemical castration of a non-human mammal related to pk/pd interaction |
WO2024003288A1 (en) * | 2022-06-30 | 2024-01-04 | Virbac | Deslorelin for attenuation of animal urine odor |
Also Published As
Publication number | Publication date |
---|---|
EP3949951A4 (en) | 2023-01-18 |
JP2022530878A (ja) | 2022-07-04 |
KR20200126599A (ko) | 2020-11-09 |
CL2021002761A1 (es) | 2022-06-03 |
JP7253287B2 (ja) | 2023-04-06 |
PE20220491A1 (es) | 2022-04-07 |
CA3137819A1 (en) | 2020-11-05 |
AU2020266058B2 (en) | 2023-04-06 |
CN113747884A (zh) | 2021-12-03 |
EP3949951A1 (en) | 2022-02-09 |
KR102249104B1 (ko) | 2021-05-07 |
MX2021012923A (es) | 2021-11-17 |
IL287361A (en) | 2021-12-01 |
CA3137819C (en) | 2024-01-09 |
AU2020266058A1 (en) | 2021-11-18 |
SG11202111521WA (en) | 2021-11-29 |
US20220202894A1 (en) | 2022-06-30 |
ZA202108300B (en) | 2023-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020222399A1 (ko) | 데슬로렐린을 포함하는 서방성 마이크로 입자 및 이의 제조 방법 | |
EP2379055B1 (en) | Method of making sustained release microparticles | |
WO2018221884A1 (ko) | 방출제어가 용이한 서방성 약물 미립자의 제조방법 | |
JP2012501321A (ja) | 溶媒交流蒸発法による徐放性マイクロスフェアの製造方法 | |
KR102101969B1 (ko) | 목시덱틴을 포함하는 마이크로 입자 및 이의 제조 방법 | |
KR20190019821A (ko) | 피나스테라이드를 포함하는 마이크로 입자 및 이의 제조 방법 | |
KR101558083B1 (ko) | 약물함유 고분자미립구 제조방법 | |
US10603278B2 (en) | Microspheres containing anthelmintic macrocyclic lactones | |
KR101663561B1 (ko) | 서방출성 미립구의 제조방법 | |
WO2020166820A1 (ko) | 피나스테라이드를 포함하는 마이크로 입자를 함유한 피하 주사용 조성물 | |
KR20100092581A (ko) | 균일한 서방출성 미립구의 제조방법 | |
US20230263730A1 (en) | Composition for sustained-release injection comprising deslorelin | |
WO2019050259A1 (ko) | 목시덱틴을 포함하는 마이크로 입자 및 이의 제조 방법 | |
WO2019203543A1 (ko) | 데옥시콜린산을 포함하는 피하 주사용 조성물 및 이의 제조 방법 | |
WO2019225924A1 (ko) | 두타스테라이드를 포함하는 마이크로 입자 및 이의 제조 방법 | |
WO2019035679A9 (ko) | 피나스테라이드를 포함하는 마이크로 입자 및 이의 제조 방법 | |
US20160074320A1 (en) | Pharmaceutical compostions comprising kisspeptin or derivatives thereof | |
US20230381199A1 (en) | Non-surgical prevention of unpleasant odor in meats and aggressive or sexual behavior in male ruminants | |
WO2024085581A1 (ko) | 염증성 질환의 치료 또는 예방을 위한 서방형 주사용 조성물 및 이의 제조 방법 | |
WO2024019596A1 (ko) | 5-알파 환원효소 저해제를 포함하는 서방성 제제 | |
WO2022270956A1 (ko) | 세마글루타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 제제 조성물 | |
KR20230157365A (ko) | 루라시돈을 포함하는 마이크로스피어 제제 및 이의 제조 및 사용 방법 | |
WO2019182319A1 (ko) | 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물의 제조 방법 및 이의 제조 방법으로 제조된 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물 | |
WO2009134092A2 (ko) | 난용성 약물 함유 서방성 고분자 나노입자 제형 | |
LTDA | 12, Patent Application Publication |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20799171 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3137819 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021563253 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021021599 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2020266058 Country of ref document: AU Date of ref document: 20200114 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020799171 Country of ref document: EP Effective date: 20211026 |
|
ENP | Entry into the national phase |
Ref document number: 112021021599 Country of ref document: BR Kind code of ref document: A2 Effective date: 20211027 |